Abstracts tagged "cytokines"

Abstract Number: 1845 • 2013 ACR/ARHP Annual Meeting
Soluble Type I Interferon Receptor 2 Is Elevated By Interferon Treatment and In Certain Autoimmune Diseases
Taher Fatakdawala¹, Michael Skawinski¹, Jonathan Ferriera², Tara Stauffer¹ and Thomas Lavoie¹, ¹Product Research & Development and Assay Services, PBL Assay Science, Piscataway, NJ, ²Quality Control, PBL Assay Science, Piscataway, NJ
Background/Purpose: The Type I Interferon (IFN) receptor is a heterodimer of chain 1 (IFNAR1) which is required for signaling, and chain 2 (IFNAR2) which binds…
Abstract Number: 934 • 2013 ACR/ARHP Annual Meeting
Interleukin-12B Is Up-Regulated By Decoy Receptor 3 In Specifically Rheumatoid Synovial Fibroblasts
Koji Fukuda¹, Yasushi Miura^1,2, Toshihisa Maeda¹, Shinya Hayashi³ and Masahiro Kurosaka³, ¹Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ³Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Decoy receptor 3 (DcR3) is a secreted decoy tumor necrosis factor receptor and competitively binds and inhibits the TNF family including Fas-ligand (FasL), LIGHT,…
Abstract Number: 2740 • 2013 ACR/ARHP Annual Meeting
High Efficacy Of Toll-Like Receptor 4 Targeting In Murine and Humanized Models Of Rheumatoid Arthritis In Comparison With IL-1 and TNF Inhibitors
Shahla Abdollahi-Roodsaz¹, Marije I. Koenders², Leo A. Joosten³, Fons A. van de Loo⁴ and Wim B. van den Berg¹, ¹Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ⁴Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: Increased expression of Toll-like Receptor (TLR) 4 and its endogenous agonists in rheumatoid joints suggest involvement in rheumatoid arthritis (RA). The aim of this…
Abstract Number: 1824 • 2013 ACR/ARHP Annual Meeting
ONO-4059 – A Novel Small Molecule Dual Inhibitor Of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase- Suppresses Osteoclastic Bone Resorption and Inflammation
Yuko Ariza¹, Toshio Yoshizawa¹, Yoshiko Ueda¹, Shingo Hotta¹, Tomoko Yasuhiro¹, Masami Narita¹, Yutaka Shichino² and Kazuhito Kawabata¹, ¹Discovery Research Laboratories 3, Ono Pharmaceutical Co., Ltd., Osaka, Japan, ²Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd., Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by leukocyte infiltration, synoviocyte hyperplasia and osteoclastogenesis, leading to erosion of the joints and cartilage,…
Abstract Number: 941 • 2013 ACR/ARHP Annual Meeting
Mir-34a In Rheumatoid Arthritis: Characterisation Of Elevated Synovial Expression and Association With Treatment Resistance
Clare E Tange¹, Stefano Alivernini², Derek S. Gilchrist³, Lynn Crawford³, Ashleigh-Ann Rainey¹, Derek Baxter³, Iain B. Mcinnes⁴ and Mariola Kurowska-Stolarska⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Cells of the monocyte/macrophage lineage are critical to RA pathogenesis: unravelling mechanisms underlying macrophage inflammatory gene expression should elucidate novel disease-associated pathways and thereby…
Abstract Number: 2657 • 2013 ACR/ARHP Annual Meeting
Interactions Between Cigarette Smoking, Body Mass Index and Inflammatory Cytokine Levels In Determining The Risk Of Developing Rheumatoid Arthritis
Elizabeth V. Arkema¹, Susan Malspeis², Bing Lu³, Linda T. Hiraki⁴, Elizabeth W. Karlson² and Karen H. Costenbader², ¹Epidemiology, Harvard School of Public Health, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA
Background/Purpose: Smoking and high body mass index (BMI) are risk factors for RA. Both are associated with increased systemic inflammation, with elevated C-reactive protein, interleukin…
Abstract Number: 1763 • 2013 ACR/ARHP Annual Meeting
IL4-10 Synerkine: A Novel Immunoregulatory Drug To Prevent Immunopathology In Rheumatic Diseases
Sarita Hartgring¹, Cristine Steen-louws², C.E. Hack³, Martin De Smet⁴, Floris Lafeber⁵ and J.A.G. van Roon⁶, ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology & Clinical Immunology/Lab Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ³Immunology, UMC Utrecht, Utrecht, Netherlands, ⁴Lab Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ⁵Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, ⁶Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: A considerable percentage of patients shows a limited response to biologics targeting one specific inflammatory mediator, largely because of redundancy of these mediators. An…
Abstract Number: 944 • 2013 ACR/ARHP Annual Meeting
Mir-125a: A Novel Regulator Of IL-6 and TLR Driven Pathways In RA Pathogenesis
Ashleigh-Ann Rainey¹, Derek S. Gilchrist², Clare E Tange¹, Marina Frleta³, Lynn Crawford², Derek Baxter², Iain B. Mcinnes⁴ and Mariola Kurowska-Stolarska⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Institute of infection, immunity and inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Molecular mechanisms driving disease initiation and chronicity in RA are incompletely understood. There is increasing interest in the role played therein by microRNAs –…
Abstract Number: 2573 • 2013 ACR/ARHP Annual Meeting
The Role Of STAT-3 In The Development Of Pulmonary and Dermal Fibrosis
Mesias Pedroza¹, Sarah To¹, Anuh T. George¹, David J. Tweardy² and Sandeep K. Agarwal¹, ¹Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX
Background/Purpose: Fibrosis is the accumulation of excessive extra-cellular matrix in tissues, leading to tissue damage. In systemic sclerosis, the trigger is postulated to be an…
Abstract Number: 1766 • 2013 ACR/ARHP Annual Meeting
Role Of IL33 In The Inflammation Of Takayasu Arteritis
David Saadoun¹, Marlène Garrido², Julien Gaudric³, Cloé Comarmond⁴, Michele Rosenzwacjg⁵ and Patrice Cacoub⁶, ¹Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ²I3 laboratory, Pitié-Salpétrière, Paris, France, ³Department of Vascular surgery GHPS, Paris, France, ⁴Internal Medicine and Clinical Imunology, Referal Center for Autoimmune diseases, Internal Medicine and Clinical Imunology, Hôpital Pitié Salpétrière, Paris, France, ⁵Department of Immunology GHPS, Paris, France, ⁶Médecine Interne 2, Hopital Pitié-Salpétrière, Paris, France
Background/Purpose: Interleukin (IL)-33, a member of the IL-1 cytokine family, is a recently described novel activator of endothelial cells, which promotes adhesion molecules and proinflammatory…
Abstract Number: 881 • 2013 ACR/ARHP Annual Meeting
Time To Renal Flare and Renal Disease Activity Over a 1 Year Period Is associated With Urinary TWEAK Levels In Patients With Systemic Lupus Erythematosus
Nicolas Wisniacki¹, Chris Stebbins², Jadwiga Bienkowska³, Susan Gawlak², Donald Bennett⁴, Yuhong Xiang⁵, Andrea Dearth⁶, Linda C. Burkly⁷, Ann Ranger⁶, Carrie Wager⁵, Laurence S. Magder⁸ and Michelle Petri⁹, ¹Medical Research, Biogen Idec, Maidenhead, United Kingdom, ²Translational Medicine, Biogen Idec, Cambridge, MA, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Biostatistics, Biogen idec, Cambridge, MA, ⁵Biostatistics, Biogen Idec, Cambridge, MA, ⁶Biogen Idec Inc, Cambridge, MA, ⁷Biogen Idec, Cambridge, MA, ⁸Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: TNF-like weak inducer of apoptosis (TWEAK) is a member of the TNF superfamily that signals through its distinct, highly inducible receptor, FGF-inducible molecule 14…
Abstract Number: 2537 • 2013 ACR/ARHP Annual Meeting
Inactive Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise
Luiz A. Perandini¹, Diego Sales-de-Oliveira¹, Suzana B.V. Mello², Niels O Camara³, Fernanda R. Lima¹, Eduardo F. Borba², Eloisa Bonfa², Ana Lucia Sá-Pinto¹, Hamilton Roschel⁴ and Bruno Gualano⁵, ¹University of Sao Paulo, Rheumatology Division, Sao Paulo, Brazil, ²University of Sao Paulo, Rheumatology Division, São Paulo, Brazil, ³Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil, ⁴Universidade de São Paulo, Faculdade de Educação Física e Esporte, São Paulo, Brazil, ⁵University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by a chronic inflammation associated with worse cardiovascular outcome. Although a few studies have…
Abstract Number: 1767 • 2013 ACR/ARHP Annual Meeting
Gender, Race, and Soluble Mediators Distinguish Blood Relatives Who Develop Incomplete Lupus Or Classified SLE In The Lupus Autoimmunity In Relatives (LAUREL) Study
Melissa E. Munroe¹, Kendra A. Young², Jill M. Norris², Joel M. Guthridge³, Diane L. Kamen⁴, Timothy B. Niewold⁵, Gary S. Gilkeson⁴, Michael H. Weisman⁶, Mariko L. Ishimori⁶, Daniel J. Wallace⁷, David R. Karp⁸, John B. Harley^9,10 and Judith A. James^11,12, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Healthy blood relatives (FDRs) of lupus…
Abstract Number: 842 • 2013 ACR/ARHP Annual Meeting
A Cytokine/Chemokine Multiplex Assay That Is Sensitive and Specific For Fibromyalgia Compared To Controls, Systemic Lupus Erythematosus, and Rheumatoid Arthritis
Daniel J. Wallace¹, Igor Gavin², Oleksiy Karpenko² and Bruce S. Gillis³, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of Illinois College of Medicine at Chicago, Chicago, IL, ³Department of Pathology, University of Illinois College of Medicine at Chicago, Chicago, IL
Background/Purpose: Fibromyalgia (FM) is a chronic pain and fatigue syndrome that affects about 6 million adults in the United States. The clinical diagnosis of…
Abstract Number: 2545 • 2013 ACR/ARHP Annual Meeting
Active Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise
Luiz A. Perandini¹, Diego Sales-de-Oliveira¹, Suzana B.V. Mello², Niels O Camara³, Fernanda R. Lima¹, Eduardo F. Borba², Eloisa Bonfa², Ana Lucia Sá-Pinto¹, Hamilton Roschel⁴ and Bruno Gualano⁵, ¹University of Sao Paulo, Rheumatology Division, Sao Paulo, Brazil, ²University of Sao Paulo, Rheumatology Division, São Paulo, Brazil, ³Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil, ⁴Universidade de São Paulo, Faculdade de Educação Física e Esporte, São Paulo, Brazil, ⁵University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is a rheumatic autoimmune condition characterized by altered lipoprotein profile, physical dysfunction and increased risk of cardiovascular disease. Exercise is,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].